Reporting
Camu Camu effects on circulating LPS and systemic immune activation in ART-treated participants
Learn MoreEnrolling
Vedolizumab treatment in antiretroviral drug treated chronic HIV infection, followed by analytical treatment interruption (HIV-ART-vedolizumab-ATI)
Learn MoreCompleted
The effect of metformin on HIV reservoir size in non-diabetic ART-treated patients
Learn MoreReporting
Terminated
Probiotic Visbiome for Inflammation and Translocation in HIV (PROOV IT I)
Learn MoreTerminated
A pilot randomized, open label study to evaluate the effect of a therapeutic HIV vaccine consisting of PENNVAX®-GP (gag, pol, env) and INO-9012 DNA vaccine delivered via electroporation on reducing HIV viral reservoirs in infected individuals, who initiated therapy during the acute/early phase of infection
Learn MoreCompleted
Role of extended-released niacin on immune activation in HIV-infected patients treated with antiretroviral therapy: a proof-of-concept study
Learn More
CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.
